Pharmesis International Ltd. announced unaudited consolidated earnings results for third quarter and nine months ended September 30, 2017. For the quarter, the company reported revenue of RMB 17,317,000 against RMB 16,593,000 for the same period a year ago. Profit from operations was RMB 590,000 against loss from operations of RMB 296,000 for the same period a year ago. Profit before tax was RMB 392,000 against loss before tax of RMB 447,000 for the same period a year ago. Loss for the period was RMB 81,000 against RMB 447,000 for the same period a year ago. Loss attributable to equity holders of the company was RMB 198,000 against RMB 279,000 for the same period a year ago. Net cash flows from operating activities were RMB 4,538,000 against RMB 1,910,000 for the same period a year ago. Acquisition of property, plant and equipment was RMB 80,000 against RMB 184,000 for the same period a year ago. Loss on fully diluted basis was 0.86 cents against 1.21 cents for the same period a year ago. For the nine months, the company reported revenue of RMB 51,013,000 against RMB 48,181,000 for the same period a year ago. Profit from operations was RMB 995,000 against loss from operations of RMB 1,278,000 for the same period a year ago. Profit before tax was RMB 451,000 against loss before tax of RMB 1,761,000 for the same period a year ago. Loss for the period was RMB 22,000 against RMB 1,770,000 for the same period a year ago. Loss attributable to equity holders of the company was RMB 1,081,000 against RMB 1,829,000 for the same period a year ago. Net cash flows from operating activities were RMB 4,282,000 against RMB 1,793,000 for the same period a year ago. Acquisition of property, plant and equipment was RMB 1,051,000 against RMB 513,000 for the same period a year ago. Loss on fully diluted basis was 4.70 cents against 7.95 cents for the same period a year ago.